Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.

Show other versions (1)

BACKGROUND: Tumour necrosis factor (TNF)-alpha inhibitors are beneficial for the treatment of rheumatoid arthritis (RA) in terms of reducing the risk of joint damage, improving physical function and improving quality of life. This Cochrane review is an update of a review of the treatment of RA with...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron:	Ruiz Garcia, V, Jobanputra, P, Burls, A, Cabello, J, Vela Casasempere, P, Bort-Marti, S, Kynaston-Pearson, F
Fformat:	Journal article
Iaith:	English
Cyhoeddwyd:	2014

Eitemau Tebyg

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
gan: Ruiz Garcia, V, et al.
Cyhoeddwyd: (2011)

Certolizumab pegol in therapy for rheumatoid arthritis
gan: Galina Viktorovna Lukina, et al.
Cyhoeddwyd: (2012-06-01)

Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis
gan: M Connock, et al.
Cyhoeddwyd: (2010-10-01)

QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL
gan: Vera Nikolayevna Amirdjanova, et al.
Cyhoeddwyd: (2012-10-01)

New aspects of the pharmacotherapy of rheumatoid arthritis: a focus on certolizumab pegol
gan: Evgeniy L'vovich Nasonov, et al.
Cyhoeddwyd: (2011-02-01)

Multifocal tuberculosis on certolizumab pegol in a patient followed for rheumatoid arthritis
gan: Emna Hannech, et al.
Cyhoeddwyd: (2021-06-01)

New treatment possibilities for rheumatoid arthritis: the Russian experience in using certolizumab pegol
gan: Dmitry Evgenyevich Karateev, et al.
Cyhoeddwyd: (2012-04-01)

EFFICACY OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF PSORIATIC ARTHRITIS
gan: T. V. Korotaeva, et al.
Cyhoeddwyd: (2015-10-01)

Certolizumab pegol – new option in the treatment of psoriatic arthritis
gan: Maria Majdan, et al.
Cyhoeddwyd: (2014-07-01)

Certolizumab pegol in the treatment of spondyloarthritis
gan: Mariusz Korkosz
Cyhoeddwyd: (2014-09-01)

Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis
gan: Smolen, JS, et al.
Cyhoeddwyd: (2024)

COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL PLUS METHOTREXATE OR AS MONOTHERAPY FOR THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS IN THE UNITED KINGDOM
gan: Purcaru, O, et al.
Cyhoeddwyd: (2010)

Prefilled certolizumab pegol (Cimzia&reg;) syringes for self-use in the treatment of rheumatoid arthritis
gan: J Rosa, et al.
Cyhoeddwyd: (2010-08-01)

CERTOLIZUMAB PEGOL IN THE TREATMENT OF AXIAL SPONDYLOARTHRITIS
gan: Sh. F. Erdes
Cyhoeddwyd: (2016-02-01)

Eosinophilic Annular Erythema Due to Certolizumab Pegol Therapy for Rheumatoid Arthritis Post-COVID-19 Vaccine
gan: Andrea Bassi, et al.
Cyhoeddwyd: (2023-04-01)

The efficacy of certolizumab pegol in rheumatoid arthritis assessed by gray scale and power Doppler ultrasonography: case reports
gan: José Alexandre Mendonça, et al.
Cyhoeddwyd: (2019-02-01)

Exposure–Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis
gan: Stéphane Paul, et al.
Cyhoeddwyd: (2020-07-01)

Drug Induced Thrombotic Microangiopathy with Certolizumab Pegol
gan: Mehmet Baysal, et al.
Cyhoeddwyd: (2018-09-01)

Treatment of pyoderma gangrenosum in pregnancy with certolizumab pegol
gan: Lindsey J. Wanberg, et al.
Cyhoeddwyd: (2024-06-01)

Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post-hoc analysis of clinical trials
gan: Tanaka, Y, et al.
Cyhoeddwyd: (2023)

Experience with long-term use of certolizumab pegol (Cimzia)
gan: Karine Arnoldovna Lytkina, et al.
Cyhoeddwyd: (2013-10-01)

Experience with long-term use of certolizumab pegol (Cimzia)
gan: Karine Arnoldovna Lytkina, et al.
Cyhoeddwyd: (2013-10-01)

A genome-wide screen for variants influencing certolizumab pegol response in a moderate to severe rheumatoid arthritis population.
gan: Ian R White, et al.
Cyhoeddwyd: (2022-01-01)

A genome-wide screen for variants influencing certolizumab pegol response in a moderate to severe rheumatoid arthritis population
gan: Ian R. White, et al.
Cyhoeddwyd: (2022-01-01)

Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data
gan: Vivian P. Bykerk, et al.
Cyhoeddwyd: (2023-02-01)

Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study
gan: Glatt, S, et al.
Cyhoeddwyd: (2019)

Quantitation of certolizumab pegol by validated liquid chromatography methods
gan: Clóvis Dervil Appratto Cardoso Júnior, et al.
Cyhoeddwyd: (2023-11-01)

Certolizumab pegol in treatment of Crohn's disease with perianal lesions
gan: I.L. Khalif, et al.
Cyhoeddwyd: (2018-04-01)

Active axial spondyloarthritis: potential role of certolizumab pegol
gan: Ranatunga S, et al.
Cyhoeddwyd: (2014-02-01)

Certolizumab pegol w leczeniu reumatoidalnego zapalenia stawów
gan: Piotr Wiland, et al.
Cyhoeddwyd: (2011-08-01)

An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy
gan: Acosta-Felquer ML, et al.
Cyhoeddwyd: (2016-03-01)

CERTOLIZUMAB PEGOL IN THE TREATMENT OF TAKAYASU ARTERITIS: THE FIRST EXPERIENCE AND PROSPECTS
gan: P. I. Novikov, et al.
Cyhoeddwyd: (2018-07-01)

Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol.
gan: Hazes, J, et al.
Cyhoeddwyd: (2010)

Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis
gan: A. Spadaro, et al.
Cyhoeddwyd: (2013-07-01)

Patient Adherence and Efficacy of Certolizumab Pegol in the Management of Crohn's Disease
gan: Wojciech Blonski, et al.
Cyhoeddwyd: (2012-04-01)

Efficacy and tolerability of certolizumab pegol in Crohn's disease in clinical practice
gan: O V Knyazev, et al.
Cyhoeddwyd: (2018-06-01)

Certolizumab pegol – Tumor necrosis factor inhibitor for refractory uveitis
gan: Yael Sharon, et al.
Cyhoeddwyd: (2020-06-01)

Possible relationship between certolizumab pegol and arrhythmias: report of two cases
gan: R. Talotta, et al.
Cyhoeddwyd: (2016-09-01)

Effectiveness of Certolizumab Pegol in Treating Rheumatoid Arthritis Patients with Persistent Inflamed Residual Mono- or Oligosynovitis Resistant to Prior TNF-α Inhibitors
gan: Syuichi Koarada, et al.
Cyhoeddwyd: (2015-01-01)

Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment
gan: Jeffrey R. Curtis, et al.
Cyhoeddwyd: (2017-12-01)